- Research article
- Open Access
Epigenetic regulation of CD44in Hodgkin and non-Hodgkin lymphoma
BMC Cancer volume 10, Article number: 517 (2010)
Epigenetic inactivation of tumor suppressor genes (TSG) by promoter CpG island hypermethylation is a hallmark of cancer. To assay its extent in human lymphoma, methylation of 24 TSG was analyzed in lymphoma-derived cell lines as well as in patient samples.
We screened for TSG methylation using methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) in 40 lymphoma-derived cell lines representing anaplastic large cell lymphoma, Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), Hodgkin lymphoma and mantle cell lymphoma (MCL) as well as in 50 primary lymphoma samples. The methylation status of differentially methylated CD44 was verified by methylation-specific PCR and bisulfite sequencing. Gene expression of CD44 and its reactivation by DNA demethylation was determined by quantitative real-time PCR and on the protein level by flow cytometry. Induction of apoptosis by anti-CD44 antibody was analyzed by annexin-V/PI staining and flow cytometry.
On average 8 ± 2.8 of 24 TSG were methylated per lymphoma cell line and 2.4 ± 2 of 24 TSG in primary lymphomas, whereas 0/24 TSG were methylated in tonsils and blood mononuclear cells from healthy donors. Notably, we identified that CD44 was hypermethylated and transcriptionally silenced in all BL and most FL and DLBCL cell lines, but was usually unmethylated and expressed in MCL cell lines. Concordant results were obtained from primary lymphoma material: CD44 was not methylated in MCL patients (0/11) whereas CD44 was frequently hypermethylated in BL patients (18/29). In cell lines with CD44 hypermethylation, expression was re-inducible at mRNA and protein levels by treatment with the DNA demethylating agent 5-Aza-2'-deoxycytidine, confirming epigenetic regulation of CD44. CD44 ligation assays with a monoclonal anti-CD44 antibody showed that CD44 can mediate apoptosis in CD44+ lymphoma cells. CD44 hypermethylated, CD44- lymphoma cell lines were consistently resistant towards anti-CD44 induced apoptosis.
Our data show that CD44 is epigenetically regulated in lymphoma and undergoes de novo methylation in distinct lymphoma subtypes like BL. Thus CD44 may be a promising new epigenetic marker for diagnosis and a potential therapeutic target for the treatment of specific lymphoma subtypes.
Cancer cells display multiple defects in cellular pathways that govern normal cellular proliferation and homeostasis. During their development cancer cells acquire a set of functional capabilities for malignant growth, usually including self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion from apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis . These essential alterations in cell physiology are, amongst others, achieved by the constitutive activation of oncogenes and the loss of tumor suppressor gene (TSG) function. Both, genetic and epigenetic mechanisms contribute to the inactivation of TSG. Genetic alterations often include deletions and loss-of-function mutations. Furthermore, TSG may become epigenetically silenced by hypermethylation of CpG islands located in their promoter regions, which are usually unmethylated in normal tissue [2, 3]. Cytosine methylation of CpG dinucleotides is catalyzed by DNA methyltransferases . DNA methylation interferes with binding of transcription factors and, additionally, methylated CpG are bound by methyl-CpG binding proteins that induce the formation of inactive chromatin by interacting with histone deacetylases, resulting in transcriptional repression [2, 5]. Epigenetic silencing of TSG is potentially reversible. Thus, hypermethylated TSG promoters represent therapeutic targets for DNA demethylating agents like 5-Aza-2'-deoxycytidine (Aza, Decitabine), as already demonstrated in clinical trials .
TSG hypermethylation in cancer cells has strong specificity with respect to the tissue of origin and tumor-type-specific methylation patterns have been reported for primary human tumors and cancer cell lines [7–11]. Several studies showed differential DNA methylation patterns and discovered subtype-specific epigenetic markers in diverse lymphoid malignancies [12–15]. Furthermore, hypermethylation of certain TSG can be correlated with prognosis [16–18]. Yet, functional and genetic studies are necessary for the determination of lymphomagenesis-relevant hypermethylation events.
We aimed to analyze TSG methylation patterns in a broad spectrum of Hodgkin lymphoma-(HL) and non-Hodgkin lymphoma-(NHL) derived cell lines and primary samples to identify novel characteristic methylation patterns of TSG. Besides the discovery of generally hypermethylated TSG, we identified TSG with subtype-specific methylation patterns. One of these novel candidates was CD44, formerly described as lymphocyte homing receptor . CD44 hypermethylation resulting in gene silencing has already been reported for other cancer types like prostate cancer and neuroblastoma [20–22]. Recently, CD44 has been shown to be a novel translocation partner of IGH in mature B-cell malignancies resulting in overexpression of CD44 lacking exon 1 .
We show here, that CD44 was frequently hypermethylated and transcriptionally silenced in anaplastic large cell lymphoma (ALCL), Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) cell lines, whereas it was unmethylated and expressed in most HL and mantle cell lymphoma (MCL) cell lines. Importantly, this methylation and expression pattern resembled that of primary lymphomas. Experiments with a DNA demethylating agent verified epigenetic regulation of CD44. Furthermore, CD44 hypermethylated cell lines were resistant towards anti-CD44 induced apoptosis. This supports a tumor suppressor role for CD44 in lymphoma and highlights CD44 as an interesting new potential epigenetic marker and a valuable target for epigenetic therapy in distinct lymphoma subtypes.
Human cell lines
Cell lines were either resourced from the DSMZ cell repository (Braunschweig, Germany) or were generously provided by original investigators. Detailed references and cultivation protocols have been described previously .
Samples and patients
DNA was extracted from tumor containing tissues diagnosed or suspicious for Burkitt lymphoma/leukemia, in which chromosome analysis revealed the presence for a Burkitt translocation t(8;14) or variants, and from frozen sections of DLBCL and MCL from untreated patients using the DNeasy Mini Kit (Qiagen, Hilden, Germany). The study on BL material was performed according to the protocols of the network "Molecular Mechanisms in Malignant Lymphoma" for which approval by the Ethics Committee of the Medical Faculty of the Christian-Albrechts-University Kiel was obtained. The study on DLBCL and MCL material was approved by the local Ethics Committee of the Medical Faculty of the University of Würzburg.
Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)
The MS-MLPA assay (ME001B; MRC-Holland, Amsterdam, Netherlands) simultaneously detects copy number changes and CpG methylation of the promoter regions of 24 different TSG. This semi-quantitative technique is based on digestion of DNA with the methylation-sensitive restriction enzyme HhaI (Fermentas, St. Leon-Rot, Germany) and a subsequent multiplex PCR followed by fragment analysis via capillary electrophoresis . MS-MLPA data were analyzed using a Microsoft Excel spreadsheet from the National Genetics Reference Laboratory designed specifically for the ME001B assay http://www.ngrl.org.uk/Manchester/projects/informatics/mlpa. Levels of methylation were calculated by comparing relative peak areas of the HhaI digested ligation products with the corresponding ligation products from undigested samples. Peak areas were normalized relative to neighboring control ligation products prior to comparison. Samples with a methylation level > 10% were regarded as methylated.
Aza treatment for demethylation of DNA
5-Aza-2'-deoxycytidine (Sigma-Aldrich, Taufkirchen, Germany) dissolved in DMSO was used to verify the effect of promoter methylation on TSG expression. Cells were seeded at a density of 5 × 105/ml, Aza was added at a final concentration of 5 μM. Vehicle control cells were treated with 0.05% DMSO. After 2 days, half of the medium was replenished with medium with/without Aza (5 μM). After 3 or 4 days, cells were harvested to prepare RNA or used for CD44 detection by flow cytometry.
RNA isolation and quantitative real-time PCR
RNA was isolated using the RNeasy Mini Kit (Qiagen) including DNase digestion. Reverse transcription was performed with SuperScript II reverse transcriptase Kit (Invitrogen, Karlsruhe, Germany). qRT-PCR for gene expression analysis was performed on an Applied Biosystems 7500 SDS real-time PCR system (Darmstadt, Germany). Expression of RPS9 as endogenous control and of CD44 and CD44v6 was assessed using SYTO-82 (Molecular Probes, Leiden, Netherlands) as fluorescent dye and ImmoMix (Bioline, Luckenwalde, Germany) as PCR master mix. Primers were the following: CD44 fwd 5'-CAA TAG CAC CTT GCC CAC AAT-3', CD44 rev 5'-AAT CAC CAC GTG CCC TTC TAT GG-3', CD44v6 fwd 5'-GAT CAC CGA CAG CAC AGA CA-3', CD44v6 rev 5'-CCA TCT GTT GCC AAA CCA CTG-3', RPS9 fwd 5'-GGG AAG CGG AGC CAA CAT G-3', RPS9 rev 5'-GTT TGT TCC GGA GCC CAT ACT-3'. Relative gene expression levels were calculated using the ΔΔCt-method.
Bisulfite conversion and methylation-specific PCR (MSP)
Bisulfite conversion of DNA was performed as described by the supplier (EpiTect Bisulfite Kit, Qiagen). For methylation analysis of the CD44 (ENSEMBL ID ENSG00000026508) exon 1 region, including the regulatory promoter region described by Shtivelman and Bishop , we performed nested PCR with first-round primers CD44 BSP fwd 5'-GGT TGA ATT TAA TGG TGT AAG G-3' and CD44 BSP rev 5'-ACA ACT CAC TTA ACT CCA ATC C-3' amplifying bisulfite-converted DNA independently of the CD44 methylation status (bisulfite-specific PCR, BSP), while second-round primers for M-PCR CD44 M_fwd 5'-TCG TTG AGT TTG GCG TAG ATC-3', CD44 M_rev 5'-ACT ACC GCC GAA TCC GCG-3' and for U-PCR CD44 U_fwd 5'-GTG TTG TTG AGT TTG GTG TAG ATT-3', CD44 U_rev 5'-CAA AAA AAC TAC CAC CAA ATC CAC A-3' specifically recognized the methylated or unmethylated versions of the region. PCR products of the initial BSP were diluted 1:100 for subsequent MSP. Epitect PCR Control DNA (Qiagen) was used as control for methylated and unmethylated templates.
For bisulfite sequencing of the CD44 exon 1 region, CD44-BSP products obtained with primers CD44 BSP fwd and CD44 BSP rev (sequences see previous section), were purified and subcloned into the pGEM-Teasy plasmid vector (Promega, Mannheim, Germany). Plasmid DNA from at least eight insert-positive clones for each sample was isolated using QIAprep Spin Miniprep Kit (Qiagen) and subjected to automated sequencing. Sequences were evaluated using BiQ Analyzer http://biq-analyzer.bioinf.mpi-sb.mpg.de and had to conform to at least 90% bisulfite conversion rate. Identical clones were excluded from the analysis as well.
Analysis of CD44 protein expression by flow cytometry
For detection of CD44 on the cell surface, cells were washed and incubated with mouse anti-human CD44 mAB (clone G44-26, BD Biosciences, Heidelberg, Germany) or with the isotope-matched control mouse immunoglobulin (BD Biosciences) for 30 min at 4°C. Subsequently, cells were treated with FITC conjugated anti-mouse secondary antibody (Biozol, Eching, Germany) and Propidium Iodide (PI) (Sigma-Aldrich). Labeled cells were analyzed on a FACSCalibur (BD Biosciences) using CellQuest Pro software.
CD44 splice variant analysis
For the analysis of CD44 splice variants, reverse transcriptase PCR was performed using CD44 primers flanking all variant exons: CD44 exon 5 s fwd 5'-CAG ACA GAA TCC CTG CTA CCA-3', CD44 Exon 7 s rev 5'-GTC CTT ATA GGA CCA GAG GTT G-3'. The PCR reaction mixture was cycled for 30 s at 94°C, 30 s at 62°C, and 1 min at 72°C for 40 cycles. The PCR product of CD44 s corresponds to 142 bp. For sequencing of unknown splice variants, PCR products were sliced from agarose gel, purified with QIAquick Gel Extraction Kit (Qiagen) and subcloned into the pGEM-Teasy plasmid vector (Promega). Plasmid DNA was isolated using QIAprep Spin Miniprep Kit (Qiagen) and subjected to automated sequencing.
CD44 ligation and annexin-V staining
Cells were seeded at 106/ml in 96-well tissue culture plates and cultured in the presence of anti-CD44 mAb (clone G44-26, BD Biosciences) or the isotope-matched control mouse immunoglobulin (BD Biosciences) at a concentration of 5 μg/ml or 20 μg/ml for 24 h. Cells were then processed for apoptosis studies via annexin-V staining using the TACS Annexin-V-FITC Kit (R&D Systems, Wiesbaden, Germany) according to the manufacturer's instructions. Cells were analyzed by flow cytometry on a FACSCalibur (BD Biosciences) using CellQuest Pro software.
Results and Discussion
Screening for tumor suppressor gene methylation with MS-MLPA
Besides gene deletions, TSG are a frequent subject of promoter hypermethylation in tumor cells. Both types of alteration can result in functional loss of a TSG. To quantify epigenetic and genetic changes of 24 TSG, we used the semi-quantitative MS-MLPA assay. We screened a panel of 40 lymphoma cell lines (Figure 1) representing HL and five distinct subtypes of NHL (ALCL, BL, DLBCL, FL and MCL) and 50 primary lymphoma samples from BL, DLBCL and MCL patients (Additional File 1) to identify TSG methylation patterns and TSG deletions. As expected, control DNA of tonsils and peripheral blood mononuclear cells (PBMC) from three healthy donors showed no methylation or deletion of any TSG (Figure 1).
On average 8 ± 2.8 of 24 TSG were methylated per lymphoma cell line. TSG deletions were less frequent with an average of 2.4 ± 1.5 per cell line. The loss of one allele and methylation of the second one could be observed frequently in lymphoma cell lines for RARB (retinoic acid receptor beta) and to a lesser extent for TIMP3 (tissue inhibitor of metalloproteinase 3), IGSF4 (immunoglobulin superfamily member 4, alias CADM1) and ESR1 (estrogen receptor 1) (Figure 1). The examination of primary material from 29 BL, 10 DLBCL and 11 MCL patients with MS-MLPA showed that the average number of methylated TSG in primary material was lower (2.4 ± 2 of 24) than in cell lines (Additional File 1). The higher level of CpG island hypermethylation identified in cell lines in comparison to the primary tumors has also been reported by others . However, although cancer cell lines have an increased rate of hypermethylation of certain CpG islands, they retain the specific CpG island hypermethylation profile of each tumor cell [9, 29]. Consistently, the most frequently methylated TSG were the same in cell lines and primary samples: DAPK1 (death-associated protein kinase 1), RARB, CDH13 (cadherin 13), IGSF4, TIMP3, ESR1 and CD44.
The presence of generally and differentially methylated TSG among the lymphoma subtypes analyzed is in line with previous reports describing the existence of genes commonly hypermethylated in various tumors and genes being epigenetically silenced in a subtype-specific manner [7, 15]. Some of the observed TSG methylation patterns in lymphoma cell lines (e.g. for DAPK1, RASSF1) support previous methylation analyses performed on primary lymphoma patient material [30–33]. In addition, the MS-MLPA screening in lymphoma cell lines and primary samples led to the identification of novel TSG methylation profiles for RARB, TIMP3, CDH13, IGSF4 and ESR1 which were frequently methylated in lymphoma (Figure 1, Additional File 1).
From our point of view CD44 showed the most interesting and hitherto unknown methylation pattern: it was methylated in all BL cell lines (7/7) but not methylated in most of the MCL cell lines (1/7) (Figure 1). Furthermore, CD44 methylation was detected in 9/29 BL patient samples but not in any of the MCL patients (0/11) (Additional File 1). To our knowledge there are no reports on the potentially epigenetic regulation of CD44 in lymphoma cells.
Verification of differential CD44methylation in lymphoma
The MS-MLPA assay result is based on the methylation status of only one single CpG site in the context of an HhaI restriction site in the promoter region of a gene, rendering it suitable as a screening-method . To assess the significance of the CD44 methylation status obtained by MS-MLPA, we analyzed CD44 methylation with additional independent techniques: methylation-specific PCR (MSP) and bisulfite sequencing (Figures 2 and 3). After bisulfite conversion of DNA we determined the methylation status of CD44 with MSP in the lymphoma cell lines (Figure 2A) and primary samples (Figure 2B). According to MSP CD44 was methylated in all (7/7) BL cell lines, frequently methylated in ALCL (4/5), FL (4/6) and DLBCL (6/8) cell lines, and to a lesser extent methylated in HL (3/7) and MCL (2/7) cell lines, which matched the MS-MLPA results (Figure 2A). In accordance with the CD44 methylation pattern observed in cell lines, CD44 was frequently methylated in BL patients (18/29) but not methylated in MCL patients (0/11) (Figure 2B). In contrast only one DLBCL patient (1/10) showed CD44 methylation (Figure 2B), thus CD44 methylation occurred less frequently in DLBCL patients than in DLBCL cell lines. Overall, the results of MSP and MS-MLPA showed good concordance in cell lines (87.5%) and primary samples (74%) as well. In particular cases the different results of MS-MLPA and MSP might be the consequence of distinct CpG sites analyzed. Additionally, MSP is more sensitive than MS-MLPA.
Therefore, the methylation status of CD44 in lymphoma cell lines and primary samples was finally verified by bisulfite sequencing of the CpG island spanning exon 1 of CD44. Sequencing confirmed dense CpG methylation of CD44 in the BL cell line EB-1, which was CD44 hypermethylated according to MS-MLPA and MSP (Figure 3). In line with MS-MLPA and MSP results, the MCL cell line REC-1 showed no hypermethylation of the exon 1 region of CD44 (Figure 3). Also in primary samples bisulfite sequencing verified the MSP results: BL patient BL23 harbored clones with dense CpG methylation in the exon 1 region of CD44, whereas MCL patient MCL2 was not methylated at nearly all CpG sites analyzed. DLBCL patient DLBCL1 showed only partial methylation of the CpG sites next to the ATG codon. Furthermore, tonsil DNA of a healthy donor had a completely unmethylated CD44 exon 1 region (Figure 3). Thus, CD44 might in fact represent a TSG undergoing de novo methylation in distinct lymphoma subtypes like BL.
CD44: a novel epigenetically regulated TSG in lymphoma
Methylation of TSG has biological relevance if hypermethylation of the promoter region inhibits gene expression. To evaluate the correlation between methylation of the CD44 exon 1 region and CD44 transcription we performed quantitative real-time PCR (qRT-PCR) with cDNA from lymphoma cell lines. CD44 was expressed in all (7/7) MCL, most (5/7) HL and some (3/5) ALCL cell lines, but rarely transcribed in BL, FL and DLBCL cell lines (Figure 4A). In the majority of the lymphoma cell lines (80%), CD44 gene expression was inversely correlated with CD44 hypermethylation as highlighted by the color of the columns (Figure 4A). This is a remarkable correlation and suggests that CD44 is indeed regulated by DNA methylation in lymphoma cells.
Next, we investigated whether CD44 hypermethylation was also inversely correlated with CD44 protein expression. Cell surface CD44 protein expression was analyzed by flow cytometry with anti-CD44 (G44-26) monoclonal antibody (mAb) directed against epitope 1, recognizing all forms of CD44 . CD44 protein was expressed on lymphoma cell lines, which were positive for CD44 mRNA and predominantly unmethylated in the CD44 exon 1 region, especially in MCL and HL cell lines. Cell lines with CD44 hypermethylation were negative for CD44 mRNA and CD44 protein (Table 1, Figure 4B). Thus, CD44 hypermethylation was inversely correlated with gene transcription and protein expression in lymphoma cell lines.
To test whether CD44 expression is epigenetically regulated via promoter methylation in lymphoma, we treated cell lines with Aza, leading to DNA demethylation. The results confirmed that hypermethylation of CD44 was responsible for gene silencing since DNA demethylation resulted in reactivation of CD44 transcription in CD44 hypermethylated cell lines, but not in CD44 unmethylated cell lines as determined by qRT-PCR (Figure 5A, Table 1). Furthermore, Aza treatment resulted in induction of CD44 protein expression as shown for cell lines KARPAS-299 (ALCL), EB-1 (BL) and RAJI (BL) by flow cytometry (Figure 5B). The effect of Aza on methylated CD44 seemed to be direct since two cell lines (DOGUM and WSU-DLCL2) which were negative for CD44 despite being unmethylated, remained CD44 negative after Aza treatment (Table 1). However, these results show that DNA methylation is not the only reason for CD44 silencing and other suppressive mechanisms appear to play a role in DOGUM and WSU-DLCL2. It has been reported that BCL-6 and p53 are repressors of CD44 [35, 36]. In breast cancer CD44 can be suppressed by miR-373 and miR-520c . Alternatively, essential transcriptional activators might be missing in the CD44- and CD44 unmethylated cell lines. In accordance with this view, the CD44 promoter is reportedly stimulated by growth factors, particularly by the Ras-Erk signaling pathway . Interesting in this context is also that hypermethylated CD44 could be reactivated not only by Aza but also by cAMP in an ATRA-resistant acute promyelocytic leukemia cell line . Thus DNA methylation is one important but not exclusive mechanism regulating the expression of CD44.
Significantly, CD44 protein expression data from primary lymphoid material reported by others resemble the CD44 expression pattern, which we observed in lymphoma cell lines (Table 2). The standard CD44 isoform CD44s, skipping all variant exons, is mainly expressed in hematopoietic cells and shows high expression in normal lymphoid tissue [40–42]. Already hematopoietic progenitor cells display positivity for CD44 . In line with this, we identified no CD44 methylation in PBMC and tonsils of healthy donors thus enabling transcription of CD44 in these cells (Figures 1 and 3). Thus, lymphomas with an unmethylated CD44 regulatory region and expressing CD44s reflect their normal lymphocytic counterparts. MCL patient samples are characteristically positive for CD44s . This is in agreement with our data on MCL cell lines, showing CD44 expression and an unmethylated CD44 promoter (Table 2). Moreover, we detected no CD44 hypermethylation in MCL patients (Figure 2B, Table 2). Lymphoma cells of HL and ALCL patients have been described to be often CD44 positive [45, 46]. Consistent with these data, HL, and to a lesser extent ALCL cell lines expressed CD44 and had an unmethylated CD44 exon 1 region (Table 2). CD44 positive and negative cases have been reported for DLBCL patients and it was shown that CD44s expression is inversely correlated with clinical disease stage . However, the majority of DLBCL cell lines did not express CD44 due to promoter hypermethylation (Table 2). In NHL patients with BL or nodal FL CD44 is typically absent [45, 48]. In accordance with these reports, CD44 was not expressed and hypermethylated in all BL and most of the FL cell lines (Table 2). Furthermore, we identified frequent hypermethylation of CD44 in BL patients (Figure 2B, Table 2), implying that DNA methylation is the reason for CD44 silencing also in primary BL.
In conclusion, we propose that CD44 expression is regulated by DNA methylation not only in lymphoma cell lines, but also in the primary tumors. And we suppose that the loss of CD44 mRNA and protein expression in distinct lymphoma subtypes is the consequence of CD44 de novo methylation.
CD44 splice variant analysis
Depending on the cell type and the expression of CD44 splice variants CD44 proteins can have both oncogenic or tumor suppressor functions . In some hematological malignancies expression of CD44 variants is prognostically significant. Notably, expression of the variant isoform CD44v6 is associated with shorter overall survival in patients with aggressive NHL . Therefore, we analyzed expression of CD44v6 in CD44+ lymphoma cell lines with qRT-PCR. However, none of the 15 analyzed cell lines expressed the metastases-associated CD44v6 isoform (data not shown). Since we could not exclude the expression of any other variant isoform from these data alone, we investigated CD44 transcripts obtained by RT-PCR with primers flanking the variant exons of CD44 (Additional File 2). All CD44+ lymphoma cell lines and PBMC had the CD44s transcript. Sequencing of the other PCR product obtained revealed that CD44v10 was expressed in most of the CD44+ cell lines and PBMC, but to a significantly lesser extent than the standard isoform CD44s (Additional File 2). Interestingly, expression of CD44v10 has been reported for Hodgkin and Reed-Sternberg cells in nodular sclerosis HL patients and was associated with an unfavorable prognosis . However, CD44v10 mRNA is also present in CD34+ progenitor cells and normal peripheral blood lymphocytes .
In conclusion, the CD44+ lymphoma cell lines expressed mainly CD44s, which as major splice variant of normal lymphoid tissue is believed to exert tumor suppressor functions.
CD44hypermethylated lymphoma are resistant towards anti-CD44 induced apoptosis
Uncontrolled activation of oncogenes and the loss of TSG can promote sustained cell proliferation and tumorigenesis. Therefore, we decided to investigate whether the loss of CD44 by DNA hypermethylation in certain NHL subtypes might have functional consequences. CD44 activation by its natural ligand hyaluronic acid (HA) as well as by appropriate anti-CD44 mAbs stimulates multiple cell type-dependent CD44-associated functions, including proliferation, differentiation, migration, contact inhibition, and apoptosis . In acute myeloid leukemia cell lines, ligation of cell surface CD44 with an anti-CD44 mAb can inhibit proliferation and induce apoptosis [52, 53]. Therefore, CD44+ and CD44- lymphoma cell lines were cultivated for 24 h in the presence of an anti-CD44 mAb (G44-26) or of a matched isotope control antibody and were subsequently analyzed for induction of apoptosis via annexin-V/PI staining (Figure 6). CD44 ligation led to a considerable increase of early (annexin-V+/PI-) apoptotic cells in the CD44+ cell line REC-1 (MCL), whereas the CD44- cell line EB-1 (BL) was unaffected (Figure 6A). Thus, the anti-CD44 mAb triggered apoptosis in CD44+ and CD44 unmethylated cell lines (REC-1 and KM-H2), whereas CD44- lymphoma cell lines, which are CD44 hypermethylated, showed no response (Figure 6B). This supports a tumor suppressor function for CD44 in lymphoma. Since resistance towards apoptosis is a hallmark of most types of cancer, loss of CD44 due to de novo CpG island hypermethylation in certain lymphoma subtypes, especially observed in BL cell lines and patients may prove advantageous for the tumor cell and promote lymphomagenesis. Accordingly, it has been reported for prostate cancer that hypermethylation of the CD44 promoter is associated with the downregulation of CD44 expression during metastic progression .
The fact that CD44+ HL and MCL cell lines were sensitive to anti-CD44 induced apoptosis may allow for new therapeutic strategies by targeting cell surface CD44. Promising clinical trials of anti-CD44 antibody drug conjugates in breast cancer and head and neck squamous cell carcinoma have already been conducted . In addition, CD44 could become a valuable new epigenetic target in CD44 hypermethylated NHL for treatment with DNA methyltransferase inhibitors. Whether a combination of DNA demethylating agents and anti-CD44 mAbs might be applicable for CD44- lymphoma should be an object of future studies. In CD44- lymphoma cell lines Aza treatment alone induced apoptosis and a simultaneous incubation with anti-CD44 mAb showed no additive effects (data not shown).
Our studies on TSG methylation patterns in lymphoma cell lines and patient samples led to the identification of novel epigenetically silenced TSG, with CD44 being the most interesting one. Hypermethylation of CD44 occurred preferentially in ALCL, BL, DLBCL and FL cell lines, whereas HL and MCL cell lines were mainly unmethylated and tested positive for CD44 mRNA and protein. Concordant with the methylation pattern observed in cell lines, CD44 hypermethylation was identified frequently in BL but not in MCL patients. The CD44 expression profiles obtained from lymphoma cell lines resemble previous reports on differential CD44 expression in diverse primary lymphoma entities [45, 55]. No regulatory mechanisms for CD44 expression in lymphoma have been described so far. We show here, that CD44 expression is epigenetically regulated in lymphoma cell lines and presumably also in primary lymphoma. CD44 hypermethylation resulted in transcriptional silencing of the gene, which could be reactivated by treatment with the DNA demethylating agent Aza. Furthermore, ligation of cell surface CD44 with an anti-CD44 antibody triggered apoptosis in CD44+ lymphoma cell lines, whereas CD44- cell lines with CD44 hypermethylation were resistant towards anti-CD44 induced apoptosis. These experiments support the tumor suppressor function of CD44 in lymphoma. Therefore, epigenetic silencing of CD44 might be advantageous during lymphomagenesis and should be considered in further investigations. In the future, CD44 should be evaluated as a potential target for epigenetic therapy and as a target for antibody-based therapies in CD44+ lymphoma subtypes.
Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.
Herman JG, Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003, 349: 2042-2054. 10.1056/NEJMra023075.
Esteller M: Epigenetics in cancer. N Engl J Med. 2008, 358: 1148-1159. 10.1056/NEJMra072067.
Goll MG, Bestor TH: Eukaryotic cytosine methyltransferases. Annu Rev Biochem. 2005, 74: 481-514. 10.1146/annurev.biochem.74.010904.153721.
Bird A: DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16: 6-21. 10.1101/gad.947102.
Santos FP, Kantarjian H, Garcia-Manero G, Issa JP, Ravandi F: Decitabine in the treatment of myelodysplastic syndromes. Expert Rev Anticancer Ther. 2010, 10: 9-22. 10.1586/era.09.164.
Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, et al: Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet. 2000, 24: 132-138. 10.1038/72785.
Esteller M, Corn PG, Baylin SB, Herman JG: A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61: 3225-3229.
Paz MF, Fraga MF, Avila S, Guo M, Pollan M, Herman JG, Esteller M: A systematic profile of DNA methylation in human cancer cell lines. Cancer Res. 2003, 63: 1114-1121.
Rohrs S, Dirks WG, Meyer C, Marschalek R, Scherr M, Slany R, Wallace A, Drexler HG, Quentmeier H: Hypomethylation and expression of BEX2, IGSF4 and TIMP3 indicative of MLL translocations in acute myeloid leukemia. Mol Cancer. 2009, 8: 86-10.1186/1476-4598-8-86.
Rohrs S, Romani J, Zaborski M, Drexler HG, Quentmeier H: Hypermethylation of Death-Associated Protein Kinase 1 differentiates natural killer cell lines from cell lines derived from T-acute lymphoblastic leukemia. Leukemia. 2009, 23: 1174-1176. 10.1038/leu.2009.5.
Rahmatpanah FB, Carstens S, Guo J, Sjahputera O, Taylor KH, Duff D, Shi H, Davis JW, Hooshmand SI, Chitma-Matsiga R, et al: Differential DNA methylation patterns of small B-cell lymphoma subclasses with different clinical behavior. Leukemia. 2006, 20: 1855-1862. 10.1038/sj.leu.2404345.
Shi H, Guo J, Duff DJ, Rahmatpanah F, Chitima-Matsiga R, Al-Kuhlani M, Taylor KH, Sjahputera O, Andreski M, Wooldridge JE, et al: Discovery of novel epigenetic markers in non-Hodgkin's lymphoma. Carcinogenesis. 2007, 28: 60-70. 10.1093/carcin/bgl092.
Taylor KH, Kramer RS, Davis JW, Guo J, Duff DJ, Xu D, Caldwell CW, Shi H: Ultradeep bisulfite sequencing analysis of DNA methylation patterns in multiple gene promoters by 454 sequencing. Cancer Res. 2007, 67: 8511-8518. 10.1158/0008-5472.CAN-07-1016.
Martin-Subero JI, Kreuz M, Bibikova M, Bentink S, Ammerpohl O, Wickham-Garcia E, Rosolowski M, Richter J, Lopez-Serra L, Ballestar E, et al: New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. Blood. 2009, 113: 2488-2497. 10.1182/blood-2008-04-152900.
Sanchez-Aguilera A, Delgado J, Camacho FI, Sanchez-Beato M, Sanchez L, Montalban C, Fresno MF, Martin C, Piris MA, Garcia JF: Silencing of the p18INK4c gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood. 2004, 103: 2351-2357. 10.1182/blood-2003-07-2356.
Amara K, Trimeche M, Ziadi S, Laatiri A, Hachana M, Korbi S: Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. Ann Oncol. 2008, 19: 1774-1786. 10.1093/annonc/mdn374.
Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A, et al: Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 2002, 94: 26-32.
Gallatin WM, Weissman IL, Butcher EC: A cell-surface molecule involved in organ-specific homing of lymphocytes. Nature. 1983, 304: 30-34. 10.1038/304030a0.
Verkaik NS, Trapman J, Romijn JC, van der Kwast TH, van Steenbrugge GJ: Down-regulation of CD44 expression in human prostatic carcinoma cell lines is correlated with DNA hypermethylation. Int J Cancer. 1999, 80: 439-443. 10.1002/(SICI)1097-0215(19990129)80:3<439::AID-IJC17>3.0.CO;2-V.
Lou W, Krill D, Dhir R, Becich MJ, Dong JT, Frierson HF, Isaacs WB, Isaacs JT, Gao AC: Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res. 1999, 59: 2329-2331.
Hoebeeck J, Michels E, Pattyn F, Combaret V, Vermeulen J, Yigit N, Hoyoux C, Laureys G, De PA, Speleman F, et al: Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett. 2009, 273: 336-346. 10.1016/j.canlet.2008.08.019.
Hu XT, Chen YW, Liang AC, Au WY, Wong KY, Wan TS, Wong ML, Shen L, Chan KK, Guo T, et al: CD44 activation in mature B-cell malignancies by a novel recurrent IGH translocation. Blood. 2010, 115: 2458-2461. 10.1182/blood-2009-09-238782.
Drexler HG: Guide to Leukemia-Lymphoma Cell Lines. 2010, Braunschweig, 2
Nygren AO, Ameziane N, Duarte HM, Vijzelaar RN, Waisfisz Q, Hess CJ, Schouten JP, Errami A: Methylation-specific MLPA (MS-MLPA): simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res. 2005, 33: e128-10.1093/nar/gni127.
Shtivelman E, Bishop JM: Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol. 1991, 11: 5446-5453.
Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T: BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics. 2005, 21: 4067-4068. 10.1093/bioinformatics/bti652.
Smiraglia DJ, Rush LJ, Fruhwald MC, Dai Z, Held WA, Costello JF, Lang JC, Eng C, Li B, Wright FA, et al: Excessive CpG island hypermethylation in cancer cell lines versus primary human malignancies. Hum Mol Genet. 2001, 10: 1413-1419. 10.1093/hmg/10.13.1413.
Ueki T, Walter KM, Skinner H, Jaffee E, Hruban RH, Goggins M: Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. Oncogene. 2002, 21: 2114-2117. 10.1038/sj.onc.1205275.
Katzenellenbogen RA, Baylin SB, Herman JG: Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 1999, 93: 4347-4353.
Rossi D, Capello D, Gloghini A, Franceschetti S, Paulli M, Bhatia K, Saglio G, Vitolo U, Pileri SA, Esteller M, et al: Aberrant promoter methylation of multiple genes throughout the clinico-pathologic spectrum of B-cell neoplasia. Haematologica. 2004, 89: 154-164.
Wong IH, Chan J, Wong J, Tam PK: Ubiquitous aberrant RASSF1A promoter methylation in childhood neoplasia. Clin Cancer Res. 2004, 10: 994-1002. 10.1158/1078-0432.CCR-0378-3.
Murray PG, Qiu GH, Fu L, Waites ER, Srivastava G, Heys D, Agathanggelou A, Latif F, Grundy RG, Mann JR, et al: Frequent epigenetic inactivation of the RASSF1A tumor suppressor gene in Hodgkin's lymphoma. Oncogene. 2004, 23: 1326-1331. 10.1038/sj.onc.1207313.
Schlossman SF, Boumsell L, Gilks W, Harlan JM, Kishimoto T, Morimoto C, Ritz J, Shaw S, Silverstein R, Springer T, et al: Leucocyte typing V; white cell differentiation antigens. 1995, New York: Oxford University Press
Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM: BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000, 13: 199-212. 10.1016/S1074-7613(00)00020-0.
Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, et al: Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell. 2008, 134: 62-73. 10.1016/j.cell.2008.06.006.
Huang Q, Gumireddy K, Schrier M, le SC, Nagel R, Nair S, Egan DA, Li A, Huang G, Klein-Szanto AJ, et al: The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol. 2008, 10: 202-210. 10.1038/ncb1681.
Herrlich P, Morrison H, Sleeman J, Orian-Rousseau V, Konig H, Weg-Remers S, Ponta H: CD44 acts both as a growth-and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann N Y Acad Sci. 2000, 910: 106-118. 10.1111/j.1749-6632.2000.tb06704.x.
Abecassis I, Maes J, Carrier JL, Hillion J, Goodhardt M, Medjber K, Wany L, Lanotte M, Karniguian A: Re-expression of DNA methylation-silenced CD44 gene in a resistant NB4 cell line: rescue of CD44-dependent cell death by cAMP. Leukemia. 2008, 22: 511-520. 10.1038/sj.leu.2405071.
Haynes BF, Telen MJ, Hale LP, Denning SM: CD44--a molecule involved in leukocyte adherence and T-cell activation. Immunol Today. 1989, 10: 423-428. 10.1016/0167-5699(89)90040-6.
Terpe HJ, Koopmann R, Imhof BA, Gunthert U: Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. J Pathol. 1994, 174: 89-100. 10.1002/path.1711740205.
Stauder R, Eisterer W, Thaler J, Gunthert U: CD44 variant isoforms in non-Hodgkin's lymphoma: a new independent prognostic factor. Blood. 1995, 85: 2885-2899.
Lewinsohn DM, Nagler A, Ginzton N, Greenberg P, Butcher EC: Hematopoietic progenitor cell expression of the H-CAM (CD44) homing-associated adhesion molecule. Blood. 1990, 75: 589-595.
Aguilera NS, Chu WS, Andriko JA, Abbondanzo SL: Expression of CD44 (HCAM) in small lymphocytic and mantle cell lymphoma. Hum Pathol. 1998, 29: 1134-1139. 10.1016/S0046-8177(98)90426-9.
Fujiwara K, Yoshino T, Miyake K, Ohara N, Akagi T: Expression of a lymphocyte adhesion molecule (CD44) in malignant lymphomas: relevance to primary site, histological subtype and clinical stage. Acta Med Okayama. 1993, 47: 215-222.
Liang X, Golitz LE, Smoller BR, Meech SJ, Odom LF, Williams SA, Ryder JW: Association of expression of CD44v6 with systemic anaplastic large cell lymphoma: comparison with primary cutaneous anaplastic large cell lymphoma. Am J Clin Pathol. 2002, 117: 276-282.
Tzankov A, Pehrs AC, Zimpfer A, Ascani S, Lugli A, Pileri S, Dirnhofer S: Prognostic significance of CD44 expression in diffuse large B cell lymphoma of activated and germinal centre B cell-like types: a tissue microarray analysis of 90 cases. J Clin Pathol. 2003, 56: 747-752. 10.1136/jcp.56.10.747.
Attarbaschi A, Mann G, Schumich A, Konig M, Pickl WF, Haas OA, Gadner H, Dworzak MN: CD44 deficiency is a consistent finding in childhood Burkitt's lymphoma and leukemia. Leukemia. 2007, 21: 1110-1113.
Beham-Schmid C, Heider KH, Hoefler G, Zatloukal K: Expression of CD44 splice variant v10 in Hodgkin's disease is associated with aggressive behaviour and high risk of relapse. J Pathol. 1998, 186: 383-389. 10.1002/(SICI)1096-9896(199812)186:4<383::AID-PATH202>3.0.CO;2-A.
Bendall LJ, Bradstock KF, Gottlieb DJ: Expression of CD44 variant exons in acute myeloid leukemia is more common and more complex than that observed in normal blood, bone marrow or CD34+ cells. Leukemia. 2000, 14: 1239-1246. 10.1038/sj.leu.2401830.
Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y: CD44 in cancer. Crit Rev Clin Lab Sci. 2002, 39: 527-579. 10.1080/10408360290795574.
Charrad RS, Gadhoum Z, Qi J, Glachant A, Allouche M, Jasmin C, Chomienne C, Smadja-Joffe F: Effects of anti-CD44 monoclonal antibodies on differentiation and apoptosis of human myeloid leukemia cell lines. Blood. 2002, 99: 290-299. 10.1182/blood.V99.1.290.
Maquarre E, Artus C, Gadhoum Z, Jasmin C, Smadja-Joffe F, Robert-Lezenes J: CD44 ligation induces apoptosis via caspase-and serine protease-dependent pathways in acute promyelocytic leukemia cells. Leukemia. 2005, 19: 2296-2303. 10.1038/sj.leu.2403944.
Platt VM, Szoka FC: Anticancer therapeutics: targeting macromolecules and nanocarriers to hyaluronan or CD44, a hyaluronan receptor. Mol Pharm. 2008, 5: 474-486. 10.1021/mp800024g.
Picker LJ, Medeiros LJ, Weiss LM, Warnke RA, Butcher EC: Expression of lymphocyte homing receptor antigen in non-Hodgkin's lymphoma. Am J Pathol. 1988, 130: 496-504.
Pals ST, Horst E, Ossekoppele GJ, Figdor CG, Scheper RJ, Meijer CJ: Expression of lymphocyte homing receptor as a mechanism of dissemination in non-Hodgkin's lymphoma. Blood. 1989, 73: 885-888.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/517/prepub
We thank Thomas Burmeister (Charité, Berlin) for the provision of primary material, Elke Heiden (Christian-Albrechts University) for technical support and Roderick AF MacLeod (DSMZ) for critically reading the manuscript. This study was supported by grants to RS from the Deutsche Krebshilfe and KinderKrebsInitiative Buchholz/Holm-Seppensen.
The authors declare that they have no competing interests.
SE designed the study, performed experiments and data analyses and wrote the manuscript. BS carried out data analyses. AR, EMH and RS provided patient samples and performed DNA extractions thereof. JR made MS-MLPA analyses. MZ performed flow cytometry. HGD provided cell lines and good advice. HQ supervised the project. All authors read and approved the final manuscript.
Electronic supplementary material
Additional file 1: Methylation status and deletions of TSG in tumor samples of 29 BL, 10 DLBCL and 11 MCL patients. MS-MLPA results of primary lymphoma samples show the methylation status and copy number of 24 TSG. TSG are sorted from left to right according to the order of Figure 1. Yellow = TSG unmethylated and not deleted; green = TSG methylated and/or deleted; del = deleted; o. del = only deleted, not methylated; nd = not determined. (PDF 14 KB)
Additional file 2: CD44 variant analysis in CD44 + lymphoma cell lines. (A) Reverse transcriptase PCR was performed with primers (blue arrows) flanking all variant exons (colored exons in CD44 exon structure) of CD44 to examine expression of CD44 splice variants. (B) The agarose gel shows that the CD44s PCR product (142 bp) was the main variant present in the CD44+ lymphoma cell lines and PBMC (peripheral blood mononuclear cells). A second noticeable PCR product turned out to be the splice variant CD44v10 after sequencing analysis. As expected, CD44- cell lines (NAMALWA, HT) tested negative. (JPEG 1006 KB)
Authors’ original submitted files for images
About this article
Cite this article
Eberth, S., Schneider, B., Rosenwald, A. et al. Epigenetic regulation of CD44in Hodgkin and non-Hodgkin lymphoma. BMC Cancer 10, 517 (2010). https://doi.org/10.1186/1471-2407-10-517
- Follicular Lymphoma
- Hodgkin Lymphoma
- Mantle Cell Lymphoma
- Burkitt Lymphoma
- Anaplastic Large Cell Lymphoma